Recent Updates
Recently added Catalysts

BIIB107

Phase 1

Healthy Volunteers | Small molecule | Other |Biogen Inc.|Last Updated: Apr 15, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDBiomarker
Total Trials1
Total Enrollment84
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04593121Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult ParticipantsPHASE1 COMPLETED 84Oct 30, 2020Mar 5, 2024Apr 15, 20243 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs): Single Ascending Dose (SAD)
Day -1 up to Day 84

An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is a medically important event.

Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs): Multiple Ascending Dose (MAD)
Day -1 up to Day 169

An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is a medically important event.

Secondary Endpoints
Area Under the Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUCinf): SAD
Day 1 pre-dose and multiple time-points up to Day 84
Maximum Observed Concentration (Cmax): SAD
Day 1 pre-dose and multiple time-points up to Day 84
Time to Reach Maximum Observed Concentration (Tmax): SAD
Day 1 pre-dose and multiple time-points up to Day 84
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Cohort 1AEXPERIMENTALParticipants will receive Dose 1 of BIIB107 or placebo subcutaneous (SC) on Day 1.
Cohort 2AEXPERIMENTALParticipants will receive Dose 2 of BIIB107 or placebo SC on Day 1.
Cohort 3AEXPERIMENTALParticipants will receive Dose 3 of BIIB107 or placebo SC on Day 1.
Cohort 4AEXPERIMENTALParticipants will receive Dose 4 of BIIB107 or placebo SC on Day 1.
Cohort 7AEXPERIMENTALParticipants will receive Dose 5 of BIIB107 or placebo SC on Day 1.
Cohort 5AEXPERIMENTALParticipants will receive Dose 5 of BIIB107 or placebo intravenous (IV) on Day 1.
Cohort 8AEXPERIMENTALParticipants will receive Dose 6 of BIIB107 or placebo SC on Day 1.
Cohort 1BEXPERIMENTALParticipants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
Cohort 2BEXPERIMENTALParticipants will receive multiple doses of BIIB107 or placebo SC on approximately 4 dosing days.
Interventions
NameTypeDescription
BIIB107DRUGAdministered as specified in the treatment arm.
PlaceboDRUGAdministered as specified in the treatment arm.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites3

Key Inclusion Criteria: * Must have a body mass index (BMI) between 18 and 30 kilogram per meter square (kg/m\^2), inclusive, and must weigh at least 55 kilogram (kg) * All women of childbearing potential must practice highly effective contraception during the study and for a period of 90 days, whi...

Countries:United States
Unlock Eligibility Criteria